cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Anak Agung Gde Putra Wiraguna
Contact Email
editor.balidv@gmail.com
Phone
+6282339990824
Journal Mail Official
editor.balidv@gmail.com
Editorial Address
Dermatology and Venereology Department, Medical Faculty, Universitas Udayana/Prof. dr. I G. N. G. Ngoerah General Hospital, 3rd Floor (Jl. Diponegoro, Dauh Puri Klod, Kecamatan Denpasar Barat, Kota Denpasar, Bali 80113)
Location
Kota denpasar,
Bali
INDONESIA
Bali Dermatology Venereology and Aesthetic Journal
Published by Universitas Udayana
ISSN : 30467985     EISSN : 30467993     DOI : https://doi.org/10.51559/balidervenaesthj.v6i1.33
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health
Bali Dermatology Venereology and Aesthetic Journal is an open access; peer-reviewed journal aiming to communicate high-quality research articles, reviews, and general articles in the Dermatology, Venereology and Aesthetic field. The Journal aims to bridge and integrate the intellectual, methodological, and substantive diversity of Dermatology, Venereology and Aesthetic and to encourage a vigorous dialogue between researcher, medical scholars and practitioners. The scope of this journal includes: General dermatology Venereology Cosmetic dermatology/aesthetic Pediatric dermatology Allergy and immunology Skin and tumor surgery Tropical dermatology Genodermatosis (hereditary skin disease) Travel dermatology Traditional, Complementary, and Integrative medicine in dermatology Diagnostic method and artificial intelligence in dermatology
Arjuna Subject : Kedokteran - Dematologi
Articles 5 Documents
 1 
Search results for , issue "BDVJ - Vol. 3 No. 1 (June 2020)" : 5 Documents clear
Trends in the diagnostic approach of scabies as a neglected tropical disease `, Reqgi First Trasia
Bali Dermatology Venereology and Aesthetic Journal BDVJ - Vol. 3 No. 1 (June 2020)
Publisher : Explorer Front

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/gda7q068

Abstract

Scabies is a parasitic disease of the skin that is difficult to enforce if the clinical symptoms are not typical. The diagnosis relies on clinical symptoms to be less efficient and only has a sensitivity of less than 50% because it is difficult to distinguish active infestations, residual skin reactions, or reinfestations. Misdiagnosis results in wrong treatment and causes the patient to not recover and continues to be a source of infection for the environment. The exact diagnosis of scabies is determined by finding mites or eggs on laboratory tests, but mites are difficult to find because only a few mites infest sufferers. For this reason, various studies in the world have tried to develop diagnostic methods in the enforcement of scabies. This article will describe the trend of establishing a diagnosis of scabies, as well as the advantages and disadvantages in its application.
Vulvovaginal candidiasis (VVC): A review of the literature Ni Nyoman Lidya Trisnadewi
Bali Dermatology Venereology and Aesthetic Journal BDVJ - Vol. 3 No. 1 (June 2020)
Publisher : Explorer Front

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/nnsb5971

Abstract

Vulvovaginal candidiasis (VVC) is the second most common cause of vaginitis after bacterial vaginosis. VVC often occurs in women of reproductive age (20-40 years). Risk factors for VVC can be divided into two, such as host factors (pregnancy, hor-mone replacement, uncontrolled diabetes mellitus, immunosuppression, antibiotics, use of glucocorticoids, genetic influences) and behavioral factors (oral contracep-tives, sexual habits, hygiene, and clothes that are used). To diagnose VVC in a per-son, evaluation from anamnesis and clinical manifestation can be conducted. It can also be confirmed by laboratory examination. The management is based on the clas-sification. Uncomplicated VVC is most effectively treated with topical azoles, but a single dose of fluconazole can also be given orally. Treatment of VVC with compli-cations can be given fluconazole 150 mg for 3 days or topical azole for 7 days. However, when the VVC case that caused by non-albicans Candida not responding to conventional treatment such as antimycotics, the amphotericin B can be given to cure the disease. VVC caused by Candida glabrata can be given topical boric acid or flucytosine. This article consists of several theoretical references that have been viewed to have a better understanding of candidiasis vulvovaginitis.
Buschke Lowenstein tumor (BLT)/giant condyloma acuminatum (GCA): An immunopathogenesis insight Paulus Mario Christopher; Hartono Kosim; Ratna Sari Wijaya; Silvi Suhardi; Linda Julianti
Bali Dermatology Venereology and Aesthetic Journal BDVJ - Vol. 3 No. 1 (June 2020)
Publisher : Explorer Front

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/kajdxg43

Abstract

Buschke Lowenstein tumor (BLT)/giant condyloma acuminatum is a rare variant of sexually transmitted infection caused by human papillomavirus (HPV) type 6 and 11. HPV has its viral factors that exist to avoid immune surveillance and control through 1) infecting only the basal layer of the epithelium, 2) downregulation of host immunity, 3) suppression of proinflammatory proteins essential for viral clearance. The incidence of BLT/GCA is estimated to be 0.1% in the general population, with males having 2.7 times increased risk than females. The definitive diagnosis of BLT/GCA is typical morphology along with histopathological examination, and/or viral serotyping. Treatment of BLT/GCA requires a multidisciplinary approach, determined based on age, the extent of the lesion, organ involvement, and organ location.
Negative correlation between interleukin-2 (IL-2) serum with bacterial index in leprosy Patricia Dian Putri; Luh Made Mas Rusyati; Made Swastika Adiguna
Bali Dermatology Venereology and Aesthetic Journal BDVJ - Vol. 3 No. 1 (June 2020)
Publisher : Explorer Front

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/zngnct18

Abstract

Background: Leprosy is strongly influenced by the host immunity response. One of the cytokines that play a role in cellular immunity is IL-2. IL-2 will stimulate macrophages to activate phagocytosis and form granulomas, and this occurs in the leprosy tuberculoid type. Aim of this study was to verify the IL-2 serum levels are negatively correlated or not with bacterial index in leprosy. Methods: This study was a cross-sectional observational analytic study involving 50 leprosy subjects (41 MB and 9 PB types). Study was conducted at Dermatolovenerology Polyclinic of Sanglah General Hospital from December 2019 to March 2020. Ridley’s scale was used to determine bacterial index (BI). IL-2 serum levels were measured by ELISA. Result: The mean of IL-2 serum in PB was 75.53±10.32 pg/mL and in MB was 37.59±17.13 pg/mL. Strong negative correlation (r= -0.67; p<0.001) between serum IL-2 levels with bacterial index (CI 95%= 25.96–49.93; p<0.001) was found. Every 1 pg/mL increase in IL-2 serum levels will be accompanied by a decrease in the bacterial index of 0.039 and vice versa. Determinant coefficient shows that 42.2% of the BI is affected by the IL-2 serum levels. Low IL-2 serum levels were the risk factor of high BI 2.8 times (PR= 2.8; CI 95%= 1.444–5.519; p<0.001). Conclusion: IL-2 serum levels were found to be higher in PB than MB. There was a negative correlation between IL-2 serum levels with bacterial index. Low IL-2 serum levels were the risk factor of a high bacterial index in leprosy patients.
Urticarial manifestation in COVID-19 infection: A case report Anita M Djunaidi; Andrew Y Wirya
Bali Dermatology Venereology and Aesthetic Journal BDVJ - Vol. 3 No. 1 (June 2020)
Publisher : Explorer Front

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/wax31r28

Abstract

Background: The COVID-19 pandemic outbreak causes a worldwide health concern. As the epidemic progressed, several cutaneous manifestations are increasingly noticed; therefore, the authors hope this report will provide additional information that may benefit fellow healthcare professionals. Case report: A 45 years old Javanese female patient complained of fatigue, dry cough, dyspepsia, and reddish pruritic swelling on her face for one day. There was no fever, dyspnea, anosmia, diarrhea, or uvula, tongue, vocal cords, and the airway problem. She had no history of food or drug allergy, urticaria, other comorbidities, or any medicine consumption in the last 15 days. Facial dermatological status showed circumscribed, raised, erythematous areas of edema, slightly pruritic. Normal vital signs. Blood laboratory results: leucocyte 5.760/mL, decreased ALC 818/mL, increased NLR 5.0. Chest X-ray showed an increase in bronchovascular pattern and slight opacity on the peripheral, basal part of both hemithorax. COVID-19 rapid test was positive for IgM, and her PCR of upper-airway secretions revealed positive COVID-19 infection. The diagnoses were COVID-19 infection, dyspepsia, and urticaria. The treatments were levofloxacin, isoprinosine, chloroquine sulfate, omeprazole, fluimucyl, vitamin C, and diphenhydramine. Within three days of treatment, the urticaria started to fade off, and her overall condition improved. Conclusion: The COVID-19 poses a global challenge in the health sector, and one of its various manifestations is cutaneous symptoms. Further research is necessary to elucidate how COVID-19 triggers dermatological symptoms.

Page 1 of 1 | Total Record : 5

 1 

Filter by Year

2020 2020


Reset
Filter By Issues
All Issue BDVAJ - Volume 8, Issue 1 (2025) BDVAJ - Volume 7, Issue 2 (July 2024) BDVAJ - Volume 7, Issue 1 (January 2024) BDVAJ - Volume 6, Issue 2 (December 2023) BDVAJ - Volume 6, Issue 1 (June 2023) BDVJ - Vol. 5 No. 2 (December 2022) BDVJ - Vol. 5 No. 1 (June 2022) BDVJ - Vol. 4 No. 2 (December 2021) BDVJ - Vol. 4 No. 1 (June 2021) BDVJ - Vol. 3 No. 2 (December 2020) BDVJ - Vol. 3 No. 1 (June 2020) BDVJ - Vol. 2 No. 2 (December 2019) BDVJ - Vol. 2 No. 1 (June 2019) BDVJ - Vol. 1 No. 2 (December 2018) BDVJ - Vol. 1 No. 1 (June 2018) More Issue